Table I. Actively induced EAE in 1MOG9 or G107S mice.
Expt | Follow-up (d) | Group | n | Incidence | Onset (d) | Max. Score | AUC | Mortality |
---|---|---|---|---|---|---|---|---|
1 | 49 | 1MOG9 | 5 | 5/5 | 6.8±0.4 | 5.0±0 | 205.4±2.9 | 5/5 |
G107S | 5 | 5/5 | 6.8±0.4 | 2.0±0 | 59.9±18.9 | 0/5 | ||
2 | 38 | 1MOG9 | 7 | 7/7 | 7.6±1.1 | 5.0±0 | 117.8±38.8 | 7/7 |
G107S | 6 | 5/6 | 10.2±2.2 | 1.6±1.2 | 36.6±24.5 | 0/6 | ||
3 | 42 | 1MOG9, CD4 | 4 | 4/4 | 5.5±0.6 | 5.0±0 | 174.7±2.1 | 4/4 |
G107S, CD4 | 4 | 4/4 | 6.2±0.9 | 4.2±0.9 | 131.6±31.3 | 2/4 | ||
G107S, CD8 | 4 | 4/4 | 12.0±0.6 | 2.2±2.0 | 21.3±22.9 | 1/4 | ||
G107S, DN | 5 | 1/5 | 12.0 | 0.2±0.4 | 1.0±2.1 | 0/5 | ||
4 | 27 | 1MOG9, CD4 | 5 | 5/5 | 8.2±0.4 | 5.0±0 | 87.7±2.8 | 5/5 |
G107S, CD4 | 5 | 5/5 | 8.4±0.9 | 3.8±0.7 | 39.3±8.7 | 1/5 | ||
G107S, CD8 | 4 | 4/4 | 16.0±6.0 | 2.0±0.7 | 19.7±12.0 | 0/4 | ||
G107S, DN | 5 | 3/5 | 17.6±5.5 | 0.6±0.5 | 2.6±3.1 | 0/5 | ||
5 | 36 | 1MOG9, CD4 | 5 | 5/5 | 8.0±0.7 | 5.0±0 | 135.9±3.0 | 5/5 |
G107S, CD4 | 5 | 5/5 | 7.2±0.4 | 3.0±1.2 | 79±14.5 | 1/5 | ||
G107S, CD8 | 5 | 1/5 | 38.2±15.2 | 0.1±0.2 | 0.1±0.2 | 0/5 | ||
6 | 32 | 1MOG9, CD4 | 5 | 5/5 | 7.0±0.0 | 5.0±0 | 118.3±2.0 | 5/5 |
G107S, CD4 | 5 | 5/5 | 8.2±0.4 | 3.0±1.4 | 58.8±29.1 | 2/5 | ||
G107S, CD8 | 5 | 4/5 | 14.2±11.6 | 0.8±0.4 | 20.5±11.4 | 0/5 |